Objective—To evaluate the effects of insulin glargine and n-3 polyunsaturated fatty acid (n-3FA) supplements on carotid intima-media thickness (CIMT).

Research Design and Methods—We enrolled 1,184 people with cardiovascular (CV) disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or early type 2 diabetes in a randomized multicenter 2 × 2 factorial design trial. Participants received open-label insulin glargine (targeting fasting glucose levels ≤5.3 mmol/L [95 mg/dL]) or standard glycemic care and double-blind therapy with a 1-g capsule of n-3FA or placebo. The primary trial outcome was the annualized rate of change in maximum CIMT for the common carotid, bifurcation, and internal carotid artery segments. Secondary outcomes were the annualized rates of change in maximum CIMT for the common carotid and the common carotid plus bifurcation, respectively. Baseline followed by annual ultrasounds were obtained during a median follow-up of 4.9 years.

Results—Compared with standard care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 ± 0.0021 mm/year; \( P = 0.145 \)) and significantly reduced the secondary CIMT outcomes (differences of 0.0033 ± 0.0017 mm/year \( P = 0.049 \) and 0.0045 ± 0.0021 mm/year \( P = 0.032 \), respectively). There were no differences in the primary and secondary outcomes between the n-3FA supplement and placebo groups.

Conclusions—In people with CV disease and/or CV risk factors and dysglycemia, insulin glargine used to target normoglycemia modestly reduced CIMT progression, whereas daily supplementation with n-3FA had no effect on CIMT progression.
interventions, and follow-up procedures are those described in detail previously (22–24), with the addition of serial carotid ultrasound (CUS) examinations. The study was conducted at 32 ORIGIN centers in seven countries, selected based on interest and availability of adequate ultrasound equipment, which met preset technical specifications, and expert sonographers, who met predefined performance criteria. Funding and regulatory support were provided by Sanofi, and capsules containing n-3FA and placebo were provided by Pronova BioPharma, Norway. Project coordination, data management, and statistical analyses were independently provided by the Population Health Research Institute in Hamilton, Canada, which was also the site for the Core CUS Laboratory. The study was approved by the ethics review boards of all participating institutions, and all participants provided written informed consent.

Between 5 February 2004 and 27 December 2005, we enrolled people ≥50 years of age with dysglycemia, defined as early diabetes on no more than one oral glucose-lowering drug, impaired glucose tolerance (IGT), or impaired fasting glucose (IFG) and with known CV disease and/or CV risk factors (detailed clinical eligibility criteria are published [22–24] and are summarized in Supplementary Appendix 2). In addition, patients were required to have an adequate baseline CUS examination, defined as a scan allowing reliable measurements from a minimum of four predefined carotid arterial segments, as per the Core Ultrasound Laboratory’s review.

Randomization, study interventions, allocation concealment, and follow-up
Eligible participants were randomized by an automated telephone randomization system (using randomly varying block sizes, stratified by center) according to a 2 × 2 factorial design to 1) either insulin glargine (Lantus; Sanofi) or standard approaches to glycemic control and 2) either n-3FA (Omocar 1 g; Pronova BioPharma AS, Lysaker, Norway) containing eicosapentaenoic acid (EPA) 465 mg and docosahexaenoic acid (DHA) 375 mg or matching placebo containing ~1 g olive oil. The randomization sequence was concealed, and all study personnel (except one unblinded statistician at the project office) were unaware of the randomization procedure. The insulin glargine arm of the study used a prospective, randomized, open, blinded end point design (PROBE), so that study participants and site investigators were not blinded but all personnel at the Core CUS Laboratory and all other study personnel and investigators involved in event adjudication and data analysis were blinded to treatment assignment. Participants assigned to insulin glargine added one evening injection to their glycemic-control regimen and increased the dose at least once weekly, targeting a self-measured fasting plasma glucose (FPG) level of 5.3 mmol/L (95 mg/dL) or less. Participants assigned to standard care were treated on the basis of the investigator’s best judgment and local guidelines. The n-3FA arm of the trial was blinded to study participants, site investigators, and all local and central trial personnel.

Study visits occurred at 0.5, 1, 2, and 4 months after randomization and every 4 months thereafter. FPG and glycated hemoglobin (HbA1c) levels were measured at 4 months, 8 months, and annually, and fasting lipid levels were measured at baseline, 2 years, and study end in all participants. A food frequency questionnaire was administered at randomization, at 2 years, and at the end of the study, and the dietary intake of EPA and DHA was calculated using the Department of Agriculture National Nutrient Database for Standard Reference, release 23 (USDA Food Search for Windows, version 1.0).

Quantitative carotid ultrasonography
CUS examinations were performed at baseline and yearly thereafter until 1–1.3 years prior to the final ORIGIN study visit (average six scans per participant). The ultrasound methods have been reviewed in detail previously (25). Sonographer training, quality control, and CIMT measurements (readings) were performed by the Core Laboratory. Standardized and validated scanning and measurement protocols were used. All CUS scans were performed by trained and certified sonographers using high-resolution imaging systems with linear array transducers operating at a fundamental frequency of at least 7.5 MHz (for each subject, the same ultrasound imaging system and transducer were used throughout the study). A transverse B-mode scan was followed by a circumferential longitudinal scan, aimed at recording the maximum CIMT in each of 12 carotid artery segments (1-cm long), which were defined relative to the carotid flow divider as the near and far walls of the internal, bifurcation, and common left and right carotid arteries.

Three trained and certified readers unaware of treatment assignment performed all measurements using the Image-ProPlus software (Media Cybernetics, Silver Spring, MD). For each carotid arterial segment, the reader selected a minimum of three frames showing the thickest CIMT. The leading edge (far wall) and the trailing edge (near wall) of the boundaries between the lumen and media and the media and adventitia were traced, obtaining measurements of segment maximum and mean CIMT. Scans were read in batch fashion and in random order for each individual in order to exclude potential reader drift in measurements and to ensure use of similar anatomical landmarks. Batches were read by a single reader to avoid interreader variability. Intraclass correlation coefficients for 250 paired baseline CUS examinations performed maximum 10 days apart were 0.98 for the average maximum CIMT from 12 carotid artery segments and ranged from 0.93 to 0.98 for segment maximum and mean CIMT measurements. At study end, intraclass correlation coefficients evaluated on 26 paired CUS examinations were 0.95 for the average maximum CIMT from 12 carotid artery segments and ranged from 0.87 to 0.98 for segment maximum and mean CIMT measurements. Completeness of data by carotid arterial segment was as follows: 99% for the common carotid far wall, 96% for the common carotid near wall, 94% for the bifurcation far wall, 91% for the bifurcation near wall, 71% for the internal far wall, and 55% for the internal near wall.

Study outcomes
The primary outcome was the annualized change in the maximum CIMT for the near and far walls of the right and left common carotid, bifurcation, and internal carotid artery segments (12 carotid artery segments) based on all scans performed during the study. The secondary outcomes were the annualized change in the maximum common carotid CIMT (four segments, the near and far walls of the right and left common carotid artery segments) and the annualized change in the maximum CIMT for the common carotid and bifurcation (eight segments, the near and far walls of the right and left common carotid and bifurcation). An additional CUS outcome was the annualized change in the maximum far wall CIMT (six segments, the right and left far walls of the common carotid, bifurcation, and internal carotid artery segments). CV
outcome events were collected and adjudicated as part of the parent ORIGIN trial.

**Statistical analysis**
Sample size calculations showed that 800 participants would provide 80% power to detect a 2.5% treatment effect at the margins of the factorial, based on a repeated-measures analysis, assuming a control progression rate of 0.017 mm/year for the primary outcome, five CUS measurements per study participant, baseline average maximum CIMT of 1.15 in the treatment and control groups, a correlation between repeated measurements of 0.84 (between variance = 0.09613 and total variance = 0.11487, as estimated from another CIMT trial performed by our group in a high-risk population, the Study to Evaluate Carotid Ultrasound with Ramipril and vitamin E [SECURE] (26), and no significant interaction between the treatments. In light of possible lower CIMT progression rates, and allowing for a 5% attrition rate, we increased the sample size, which was set a priori to 1,100 participants.

All analyses are by intention to treat and were performed in SAS version 9.1 for Solaris. The primary analyses compared the primary, secondary, and additional CUS outcomes between the insulin glargine versus standard glycemic care and between the n-3FA versus the placebo groups, after confirming that there was no significant interaction between the study treatments for the primary, secondary, or additional CUS outcomes (P = 0.496, 0.749, 0.789, and 0.353, respectively, for interaction terms in the regression models). The main efficacy analysis included all participants with at least one adequate CUS examination after the baseline scan. As previously described (25,27–29), a repeated-measures linear mixed-effects model was used to analyze the annualized rate of change in maximum CIMT, including all segment maximum measurements for each patient as the dependent variables, with random intercepts and slopes as a function of time and fixed effects for geographic region, age, sex, treatment assignment for the other arm of the factorial design, carotid segment, treatment, time, and interaction between time and treatment. Testing was two sided and conducted with a 5% type I error rate. Similar analyses were used for the secondary and additional CIMT outcomes. Additional models were computed with the addition of fixed effects for baseline and average on treatment HbA1c, FPG, triglyceride, LDL cholesterol, HDL cholesterol, and blood pressure (BP) levels (entered individually and sequentially). Prespecified subgroups analyses were performed for age (above and below 65 years), sex, baseline glycemic status (diabetes or no diabetes), CV history (previous CV event or no previous CV event), baseline CIMT, HbA1c, FPG, and triglyceride levels (above and below median), and baseline treatment with statins and ACE inhibitors or angiotensin receptor blockers (ARBs). Laboratory measurements were analyzed by ANCOVA, using terms for treatment assignment to the other arm of the factorial, baseline metabolic status (known diabetes, new diabetes, or IFG/IGT), status with respect to a history of CV disease, and the baseline laboratory measurement as covariate. BP and heart rate changes were analyzed by repeated-measures analyses, and clinical outcomes were analyzed as part of the main ORIGIN trial, as previously described (22–24).

**RESULTS**

**Study population, adherence, and safety**
A total of 1,184 participants at 32 centers met clinical and CUS eligibility criteria; 580 were randomly assigned to insulin glargine, 604 to standard glycemic care, 585 to n-3FA, and 599 to placebo. Of these, 25 died before the scheduled first postrandomization CUS at the 1 year visit and 68 did not have any adequate follow-up CUS examination. In total, 1,091 patients (92.2%) had at least one adequate follow-up CUS examination. In total, 1,091 patients (92.2%) had at least one adequate follow-up CUS examination and are evaluated in the primary efficacy analysis (533 allocated to insulin glargine and 558 to standard glycemic care; 539 to n-3FA and 552 to placebo). All 1,184 participants were followed for safety and clinical outcomes for a median of 6.2 years (interquartile range [IQR] 5.8–6.5). The median time from the baseline to the study end CUS was 4.9 years (IQR 3.0–5.0). At study end, vital status was unknown in two participants (Supplementary Fig. 1).

Baseline characteristics of the 1,184 participants randomized in the GRACE study were well balanced between the treatment groups, were generally similar in the n-3FA and placebo groups (Supplementary Table 1). There were no significant differences in BP, heart rate, and in total, LDL, and HDL cholesterol levels (Supplementary Fig. 2). There were no significant differences in BP, heart rate, lipid, and glycemia measures between the n-3FA and the placebo groups (Supplementary Fig. 3). Dietary n-3FA consumption remained similar in the n-3FA and placebo groups at 2 years (median 58.8 mg/day [IQR 0.7–230] and 60.3 mg/day [0.3–230.2]) and at study end (median 95.3 mg/day [0.7–287.1] and 93.1 mg/day [1.5–268.4]).

**Changes in CV risk factor levels**
Compared with the standard care group, FPG, HbA1c, and triglyceride levels were lower in the insulin glargine group at 2 years and at study end (Fig. 1). There were no significant differences in BP, heart rate, and in total, LDL, and HDL cholesterol levels (Supplementary Fig. 2). There were no significant differences in BP, heart rate, lipid, and glycemia measures between the n-3FA and the placebo groups (Supplementary Fig. 3). Dietary n-3FA consumption remained similar in the n-3FA and placebo groups at 2 years (median 58.8 mg/day [IQR 0.7–230] and 60.3 mg/day [0.3–230.2]) and at study end (median 95.3 mg/day [0.7–287.1] and 93.1 mg/day [1.5–268.4]).

**Primary efficacy analysis: treatment effects on CIMT**
For the insulin glargine arm of the study, we observed a statistically nonsignificant reduction in CIMT progression for the
Table 1—Baseline characteristics by treatment group

| Demographic characteristics | Insulin glargine (n = 580) | Standard care (n = 604) | n-3FAs (n = 585) | Placebo (n = 559) |
|-----------------------------|-----------------------------|-------------------------|------------------|------------------|
| Mean age (years)            | 63.0 ± 7.9                  | 63.2 ± 7.8              | 63.0 ± 7.8       | 63.2 ± 7.9       |
| Women, n (%)                | 206 (35.5)                  | 223 (36.9)              | 224 (38.3)       | 205 (34.2)       |
| Geographic distribution, n (%) |                             |                         |                  |                  |
| North America               | 80 (13.8)                   | 86 (14.2)               | 81 (13.8)        | 85 (14.2)        |
| South America               | 405 (69.8)                  | 419 (69.4)              | 407 (69.6)       | 417 (69.6)       |
| Europe                      | 6 (1.0)                     | 8 (1.3)                 | 7 (1.1)          | 7 (1.1)          |
| India                       | 87 (15.0)                   | 86 (14.2)               | 86 (14.7)        | 87 (14.5)        |
| Australia                   | 2 (0.3)                     | 5 (0.8)                 | 4 (0.7)          | 3 (0.5)          |
| History of CV disease and of CV risk factors, n (%) |                 |                         |                  |                  |
| Prior CV event              | 303 (52.2)                  | 280 (46.4)              | 287 (49.1)       | 296 (49.4)       |
| Prior or new diabetes       | 524 (90.3)                  | 547 (90.6)              | 536 (91.6)       | 535 (89.3)       |
| IGT or IFG                  | 56 (9.7)                    | 57 (9.4)                | 49 (8.4)         | 64 (10.7)        |
| Hypertension                | 466 (80.3)                  | 485 (80.3)              | 466 (79.7)       | 485 (81.0)       |
| Hyperlipidemia              | 344 (59.3)                  | 363 (60.1)              | 344 (58.8)       | 363 (60.6)       |
| Current smoking             | 55 (9.5)                    | 67 (11.1)               | 59 (10.1)        | 63 (10.5)        |
| Microalbuminuria or macroalbuminuria |     |                         |                  |                  |
| Dietary EPA-DHA intake (mg/day)* | 47.3 (0.3–230.2) | 53.3 (0.3–230.2)       | 53.3 (0.7–230.0) | 53.4 (0.3–230.2) |
| Physical examination        |                             |                         |                  |                  |
| BMI (kg/m²)                 | 29.5 ± 5.4                  | 30.1 ± 5.9              | 29.8 ± 5.6       | 30.1 ± 5.8       |
| Heart rate (bpm)            | 71.1 ± 13.0                 | 70.6 ± 12.6             | 70.4 ± 12.6      | 70.6 ± 12.9      |
| Systolic BP (mmHg)          | 146.3 ± 23.1                | 146.2 ± 22.3            | 145.7 ± 21.8     | 147.8 ± 23.6     |
| Diastolic BP (mmHg)         | 84.0 ± 12.4                 | 84.0 ± 12.4             | 83.6 ± 12.0      | 84.8 ± 12.9      |
| Ankle/brachial index        | 1.16 ± 0.2                  | 1.16 ± 0.2              | 1.16 ± 0.2       | 1.16 ± 0.2       |
| Laboratory investigations   |                             |                         |                  |                  |
| FPG (mmol/L)                | 7.3 ± 2.0                   | 7.2 ± 2.1               | 7.3 ± 2.0        | 7.2 ± 2.0        |
| Glycated hemoglobin (%)     | 6.8 ± 1.0                   | 6.7 ± 1.0               | 6.8 ± 1.0        | 6.7 ± 1.0        |
| Total cholesterol (mmol/L)  | 4.9 ± 1.1                   | 4.9 ± 1.1               | 4.9 ± 1.1        | 5.0 ± 1.1        |
| HDL cholesterol (mmol/L)    | 1.1 ± 0.3                   | 1.2 ± 0.3               | 1.1 ± 0.3        | 1.2 ± 0.3        |
| LDL cholesterol (mmol/L)    | 3.0 ± 1.0                   | 2.9 ± 1.0               | 2.9 ± 1.0        | 3.0 ± 1.0        |
| Triglycerides (mmol/L)      | 1.9 ± 1.2                   | 1.9 ± 1.1               | 1.8 ± 1.0        | 1.9 ± 1.3        |
| Serum creatinine (µmol/L)   | 91.3 ± 21.2                 | 89.8 ± 22.2             | 89.9 ± 21.8      | 91.3 ± 21.2      |
| Estimated glomerular filtration rate (mL/min/1.73 m²) | 73.9 ± 17.8 | 76.0 ± 23.3 | 75.1 ± 19.5 | 74.3 ± 18.3 |
| Urinary albumin-to-creatinine ratio* | 0.7 (0.3–3.0) | 0.6 (0.3–2.1) | 0.7 (0.3–2.3) | 0.6 (0.3–3.0) |
| Cardiovascular and oral hypoglycemic drugs, n (%)† |                 |                         |                  |                  |
| Aspirin or antiplatelet agent | 365 (62.9) | 384 (63.6) | 370 (63.2) | 379 (63.3) |
| Statin                      | 235 (40.5)                  | 250 (41.4)              | 231 (39.5)       | 254 (42.4)       |
| ACE inhibitor or ARB        | 389 (67.1)                  | 416 (68.9)              | 406 (69.4)       | 399 (66.6)       |
| Thiazide diuretic           | 76 (13.1)                   | 79 (13.1)               | 76 (13.0)        | 79 (13.2)        |
| Anticoagulant               | 29 (5.0)                    | 33 (5.5)                | 37 (6.3)         | 25 (4.2)         |
| β-Blocker                   | 273 (45.1)                  | 286 (51.3)              | 298 (50.9)       | 295 (49.2)       |
| Calcium channel blocker     | 131 (22.6)                  | 140 (23.2)              | 130 (22.2)       | 141 (23.5)       |
| Metformin                   | 143 (24.7)                  | 159 (26.3)              | 145 (24.8)       | 157 (26.2)       |
| Sulfonylurea                | 244 (42.1)                  | 233 (38.6)              | 250 (42.7)       | 227 (37.9)       |
| Carotid ultrasound          |                             |                         |                  |                  |
| Average maximum CIMT (mm)   | 1.08 ± 0.34                 | 1.09 ± 0.34             | 1.08 ± 0.33      | 1.10 ± 0.35      |
| Average of maximum carotid CIMT (mm) | 0.88 ± 0.25 | 0.89 ± 0.25 | 0.87 ± 0.24 | 0.89 ± 0.26 |
| Average maximum common and bifurcation CIMT (mm) | 1.10 ± 0.33 | 1.11 ± 0.33 | 1.09 ± 0.31 | 1.12 ± 0.34 |
| Average maximum far wall CIMT (mm) | 1.08 ± 0.38 | 1.09 ± 0.34 | 1.07 ± 0.35 | 1.10 ± 0.37 |

Plus/minus values are means ± SDs. Prior vascular event refers to history of myocardial infarction, stroke, or revascularization. *Values are medians and IQRs. †At study end, 51% were taking statins, 75% ACE inhibitors or ARBs, 70% aspirin, 55% β-blockers, 28% calcium channel blockers, and 18% thiazide diuretics (similar in the treatment and control groups). At study end, metformin and sulfonylurea use were 56 and 25% in the insulin glargine and 61 and 53% in the standard care groups. Study-end use of oral hypoglycemic drugs remained well balanced between the n-3FA and placebo groups.
primary outcome and significant differences, favoring insulin glargine therapy for the secondary CIMT outcomes. These findings did not differ significantly in models adjusting for baseline and average on treatment FPG, HbA1c, lipids, and BP. There were no significant differences for the primary, secondary, and additional CIMT outcomes between the n-3FA and placebo groups (Table 2 and Fig. 2). The effect of both interventions on the primary outcome was similar across predefined subgroups (Supplementary Fig. 4) and across geographic regions.

**CV events**

Major CV events (defined as CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalized heart failure) occurred in 29.5% of participants in the insulin glargine and 29.0% in the standard care groups and in 28.4% in the n-3FA and 29.9% in the placebo groups, respectively. There were also no differences in all-cause and CV death, myocardial infarction, stroke, revascularization, and angina rates. More robust data on the effect of the study drugs on clinical events are provided by the larger, parent ORIGIN trial (23,24).

**CONCLUSIONS**—ORIGIN-GRACE is the largest reported clinical trial that evaluated the effects of insulin and n-3FA supplements on atherosclerosis progression. Insulin glargine, a basal insulin, titrated to achieve normoglycemia, significantly lowered FPG, HbA1c, and triglyceride levels and had consistent favorable effects on CIMT progression, whereas n-3FA supplements had no significant effect on glycemia, lipids, and CIMT.

Once-daily subcutaneous injections with insulin glargine were acceptable to patients, as evidenced by the high adherence rates, were generally safe, and resulted in excellent glycemic control, with mean FPG and HbA1c levels of 5.2 mmol/L and 6.0% at 1 year and 5.3 mmol/L and 6.5% at 5 years, respectively. They modestly lowered triglyceride levels and had no significant effects on BP, heart rate, and cholesterol levels. There was a statistically nonsignificant 11% reduction in the slope of CIMT progression for the primary outcome and significant 20 and 18%, respectively, for the secondary outcomes, with similar trends, 15% reduction, for the additional CIMT end point. These differences in CIMT progression could not be explained by differences in FPG and HbA1c, suggesting that these may be independent of glucose lowering.

We selected a priori as our primary study outcome the annualized change in the maximum CIMT from all 12 carotid arterial segments and found a statistically nonsignificant trend toward a lower progression rate with insulin glargine. However, the optimal CIMT outcome in clinical trials remains controversial (30,31). Whereas some groups favor the
Insulin glargine, n-3FA, and CIMT

Table 2—Main efficacy analysis: annualized changes (slopes) for the primary, secondary, and additional efficacy outcomes*

| Insulin glargine arm of the trial | Insulin glargine (n = 533) slope LSM ± SE (mm/year) | Standard care (n = 558) slope LSM ± SE (mm/year) | Difference (glargine, standard care) LSM ± SE (mm/year) | P value |
|----------------------------------|--------------------------------------------------|-------------------------------------------------|-------------------------------------------------|---------|
| **Primary outcome**              |                                                  |                                                 |                                                 |         |
| Maximum CIMT for 12 carotid artery segments | 0.0234 ± 0.0015 | 0.0264 ± 0.0015 | −0.0030 ± 0.0021 | 0.145 |
| **Secondary outcomes**           |                                                  |                                                 |                                                 |         |
| Maximum CIMT for the four common carotid artery segments | 0.0126 ± 0.0012 | 0.0158 ± 0.0012 | −0.0033 ± 0.0017 | 0.049 |
| Maximum CIMT for the eight common carotid and bifurcation segments | 0.0209 ± 0.0015 | 0.0254 ± 0.0015 | −0.0045 ± 0.0021 | 0.032 |
| **Additional outcome**           |                                                  |                                                 |                                                 |         |
| Maximum far wall CIMT for six carotid artery segments | 0.0241 ± 0.0015 | 0.0285 ± 0.0015 | −0.0044 ± 0.0023 | 0.061 |

| n-3FA arm of the trial | n-3FA (n = 539) | Placebo (n = 552) | Difference (active placebo) | P value |
|-----------------------|-----------------|------------------|-----------------------------|---------|
| **Primary outcome**   |                 |                  |                             |         |
| Maximum CIMT for 12 carotid artery segments | 0.0254 ± 0.0015 | 0.0244 ± 0.0015 | 0.0009 ± 0.0021 | 0.650 |
| **Secondary outcome** |                 |                  |                             |         |
| Maximum CIMT for the four common carotid artery segments | 0.0140 ± 0.0012 | 0.0144 ± 0.0012 | −0.0004 ± 0.0017 | 0.812 |
| Maximum CIMT for the eight common carotid and bifurcation segments | 0.0243 ± 0.0015 | 0.0221 ± 0.0015 | 0.0022 ± 0.0021 | 0.288 |
| **Additional outcome** |                 |                  |                             |         |
| Maximum far wall CIMT for six carotid artery segments | 0.0280 ± 0.0017 | 0.0247 ± 0.0016 | 0.0033 ± 0.0023 | 0.152 |

Differences in CIMT outcomes between the insulin glargine and standard care groups in additional models were as follows. Model 1 was adjusted for baseline and average on treatment HbA1c: −0.0030 ± 0.0021 (P = 0.145) for the primary outcome, −0.0033 ± 0.0017 (P = 0.051) and −0.0044 ± 0.0021 (P = 0.036) for the secondary outcomes, and −0.0045 ± 0.0023 (P = 0.061) for the additional CIMT outcome. Model 2 was adjusted for baseline and average on treatment FPG levels: −0.0030 ± 0.0021 (P = 0.145) for the primary outcome, −0.0033 ± 0.0017 (P = 0.049) and −0.0045 ± 0.0021 (P = 0.032) for the secondary outcomes, and −0.0044 ± 0.0023 (P = 0.061) for the additional CIMT outcome. Model 3 was adjusted for baseline and average on treatment HbA1c and FPG levels: −0.0031 ± 0.0021 (P = 0.146) for the primary outcome, −0.0034 ± 0.0017 (P = 0.047) and −0.0046 ± 0.0021 (P = 0.032) for the secondary outcomes, and −0.0044 ± 0.0024 (P = 0.065) for the additional CIMT outcome. There were no differences in the primary, secondary, and additional CIMT outcomes between the n-3FA and placebo groups in any models adjusted for risk factor levels. Model 4 was adjusted for baseline and average on treatment triglyceride levels: −0.0032 ± 0.0021 (P = 0.1305) for the primary outcome, −0.0034 ± 0.0017 (P = 0.043) and −0.0046 ± 0.0021 (P = 0.028) for the secondary outcomes, and −0.0045 ± 0.0023 (P = 0.056) for the additional CIMT outcome. Model 5 was adjusted for baseline and average on treatment HbA1c, FPG, triglycerides, systolic BP, diastolic BP, and LDL and HDL cholesterol: −0.0030 ± 0.0021 (P = 0.153) for the primary outcome, −0.0035 ± 0.0017 (P = 0.041) and −0.0045 ± 0.0021 (P = 0.034) for the secondary outcomes, and −0.0044 ± 0.0024 (P = 0.066) for the additional CIMT outcome. *Insulin glargine reduced FPG, HbA1c, and triglyceride levels and had no effect on BP, heart rate, and LDL and HDL cholesterol. Additional models adjusted for baseline and average on treatment levels of these variables did not significantly alter the differences in the primary, secondary, or additional outcomes between the insulin and standard care group. LSM, least squares mean.

change in the maximum CIMT across 12 carotid segments (as a more comprehensive approach), others favor changes in our predefined secondary outcomes (i.e., the common carotid and the common carotid plus bifurcation segments), due to fewer missing data and higher reproducibility (especially for the common carotid artery), or our additional CIMT outcome, because of higher accuracy for far wall measurements (30,31). Indeed, in our trial, missing data were highest for the internal carotid artery segments.

Our findings provide further data supporting the CV safety of insulin glargine. The parent ORIGIN trial found no increase in clinical CV events with insulin glargine after 6.2 years, and the GRACE substudy found no adverse effects on atherosclerosis after 5 years. Diabetic patients frequently require glycemic control for decades. The lack of adverse effects of basal insulin on the arterial wall over 5 years suggests that longer-term therapy is likely to remain safe with regards to CV outcomes and may result in clinical CV benefits. The Food and Drug Administration recently mandated proof of CV safety as a major requirement for the approval of new hypoglycemic drugs (32). The findings of ORIGIN and its atherosclerosis substudy, GRACE, provide a very robust body of evidence for the CV safety of insulin glargine.

In experimental studies, insulin reduced inflammatory markers (5,33) and improved endothelial function (34) and atherogenic plasma lipid patterns (35), although some studies suggested a possible proatherogenic effect of exogenous insulin in insulin-resistant states associated with compensatory hyperinsulinemia, possibly by stimulating cell proliferation through the MAPK pathway (6,7). There are surprisingly few studies on the effects of insulin on human atherosclerosis progression. The long-term follow-up of the Diabetes Control and Complications Trial.

*Diabetes Care* care.diabetesjournals.org
DCCT) cohort, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which compared CIMT in 1,229 patients with type 1 diabetes, 611 who had been randomly assigned to conventional diabetes treatment during the DCCT and 618 to intensive insulin treatment, found that 6 years after completion of the randomized DCCT intervention trial, CIMT was significantly lower in the group that had received intensive insulin therapy during the trial (36). Several studies confirmed the presence of increased CIMT in people with type 2 diabetes or prediabetes (37). However, there are only a few small, and therefore not reliable, intervention trials with insulin on atherosclerosis progression (38,39). Clinical CV end point trials conducted prior to ORIGIN also fail to provide clear answers regarding the impact of exogenous insulin on CV events. Extended follow-up of the UK Prospective Diabetes Study (UKPDS) trial found a

**Figure 2**—Changes in the primary and secondary CIMT outcomes by treatment group for the insulin glargine (A) and n-3FA (B) arms of the trial (slopes of carotid intima-media change and 95% CIs). BIF, bifurcation; CC, common carotid.

**A**

- Maximum CIMT
- Maximum CC CIMT
- Maximum CC and BIF CIMT

**B**

- Maximum CIMT
- Maximum CC CIMT
- Maximum CC and BIF CIMT

Glargine = Blue; Standard Care=Red

N-3 Fatty Acid Supplements =Green; Placebo=Orange
n-3FA supplements in high-risk people, passive extended follow-up, the ORIGIN currently under evaluation in the ORIGIN CV event reduction. This hypothesis is atherosclerosis. Our insulin glargine over 4.9 years had a modest finding does not address the CV effects of dietary preventive trials will provide further insight into the role of n-3FA supplements in these differences translate into clinical event reduction.

n-3FA were reported to have several potentially antiatherogenic effects, such as improving endothelial function, lowering BP, inhibiting platelet aggregation, reducing triglycerides, and raising HDL2 cholesterol levels (8). Observational studies indicate associations between n-3FA intake and lower risk of CV events, and some clinical trials found clinical CV event reduction with n-3FA supplements (8–15). We found no significant effects of daily intake over 4.9 years of 1 g of n-3FA supplements on BP, lipid levels, and CIMT, and the parent ORIGIN trial found no effect on clinical CV events over 6.2 years (24). This is consistent with the results of previous smaller studies examining the effects on carotid and coronary atherosclerosis (17,20,21), as well as a recent meta-analysis of the effects of n-3FA on clinical outcomes (16). It is unclear if these findings are unique to our study population and the n-3FA dose and formulation used. Ongoing clinical end point trials will provide further insight into the role of n-3FA supplements in CV prevention (24). Moreover, our study does not address the CV effects of dietary fish consumption.

In conclusion, treatment with basal insulin glargine over 4.9 years had a modest beneficial effect, whereas 1 g of n-3FA supplements had no impact on carotid atherosclerosis. Our findings confirm the CV safety of insulin and raise the possibility that longer-term treatment might result in CV event reduction. This hypothesis is currently under evaluation in the ORIGIN passive extended follow-up, the ORIGIN and Legacy Effects (ORIGINALE) study. Our findings do not support the use of n-3FA supplements in high-risk people with dysglycemia.

Acknowledgments—This study was funded by Sanofi. Pronova BioPharma provided capsules containing n-3FA and placebo. E.M.L. and H.K. received grant support from Sanofi. L.R. received consulting fees from Bristol-Myers Squibb and AstraZeneca, grant support from AFA Insurance and the Swedish Heart-Lung Foundation, and lecture fees from Roche and Sanofi. Y.S. received grant support and consulting and lecture fees from Sanofi. H.C.G. received consulting and lecture fees from Sanofi and other funds through his institution from Sanofi, consulting and lecture fees from Bayer, consulting fees from Merck and other funds through his institution from Eli Lilly, and other funds through his institution from Boehringer Ingelheim. No other potential conflicts of interest relevant to this article were reported. E.M.L. designed the trial, obtained funding, supervised the activities of the Core Ultrasound Laboratory, analyzed data, interpreted results, and drafted the manuscript. J.B., S.Y., and H.C.G. designed the trial, obtained funding, interpreted results, and critically reviewed the manuscript. R.D., P.L.-J., A.R., N.H., M.H., and H.K. acquired data and critically reviewed the manuscript. L.R. designed the trial and critically reviewed the manuscript. S.S. coordinated the Core Ultrasound Laboratory activities and critically reviewed the manuscript. M.J.M. directed the Core Biochemistry Laboratory and critically reviewed the manuscript. L.D. conducted the statistical analysis. E.M.L. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Parts of this study were presented in abstract form in a Hot Line presentation at the European Society of Cardiology Congress 2012, Munich, Germany, 25–29 August 2012.

References
1. Seshasai SR, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222
2. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011;14:575–585 [PubMed]
3. Muntoni F, Muntoni S, Drannin B. Effects of chronic hyperinsulinaemia in insulin-resistant patients. Curr Diab Rep 2008;8:233–238
4. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222
5. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011;14:575–585 [PubMed]
6. Muntoni F, Muntoni S, Drannin B. Effects of chronic hyperinsulinaemia in insulin-resistant patients. Curr Diab Rep 2008;8:233–238
7. Nachsh S, Bailon O, Wyatt J, et al. Vasculotoxic effects of insulin and its role in atherosclerosis: what is the evidence? Curr Atheroscler Rep 2011;13:123–128
8. Saravanavan P, Davidson NC, Schmidt EB, Calder PC. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010;376:540–550
9. Kromhout D, Bosschieter EB, de Lezenne Coullier C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205–1209
10. Doneck TA, Grandits G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet 1991;66:205–216
11. Sekikawa A, Ueshima H, Kadowaki T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in white men in the United States in the post-World War II birth cohort. Am J Epidemiol 2007;165:617–624 [PubMed]
12. Sekikawa A, Curb JD, Ueshima H, et al.; ERA JUMP (Electron-Beam Tomography, Risk Factor Assessment Among Japanese and U.S. Men in the Post-World War II Birth Cohort) Study Group. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008;52:417–424
13. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757–761
14. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico Lancet 1999;354:447–455
15. Yokoyama M, Origasa H, Matsuoka M, et al.; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090–1098
16. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between
omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024–1033

17. Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC; HARP Research Group. Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 1995;25:1492–1498

18. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477–485

19. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554–562

20. Angerer P, Kothny W, Stöck J, von Schacky C. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res 2002;54:183–190

21. Hjerkinn EM, Abdelnoor M, Breivik L, et al. ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular and carotid intima-media thickness in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919–925

22. Crouse JR, 3rd, Rachlen JS, Riley WA, et al; METEOR Study Group. Effect of rosvuastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344–1353

23. Kastelein JJ, van Leuven SI, Burgess L, et al; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620–1630

24. Origin Trial Investigators, Gerstein HC, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26–32

25. Lonn EM, Gerstein HC, Sheridan P, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol 2009;53:2028–2035

26. Lonn E, Yusuf S, Dzavik V, et al; SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919–925

27. Crouse JR, 3rd, Rachlen JS, Riley WA, et al; METEOR Study Group. Effect of rosvuastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344–1353

28. Kastelein JJ, van Leuven SI, Burgess L, et al; RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620–1630

29. Bots ML, Visseren FL, Evans GW, et al; RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153–160

30. Bots ML, Evans GW, Riley WA, Grobbbee DE. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003;34:2985–2994

31. Dogan S, Kastelein JJ, Grobbbee DE, Bots ML. Mean common or mean maximum carotid intima-media thickness as primary outcome in lipid-modifying intervention studies. J Atheroscler Thromb 2011;18:946–957 [PubMed]

32. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. December 2008; www.fda.gov/downloads/Drugs/.../Guidances/ucm071627.pdf, accessed October, 2012.

33. Chaudhuri A, Janicke D, Wilson MF, et al. Anti-inflammatory and prothrombinolytic effect of insulin in acute ST-segment-elevation myocardial infarction. Circulation 2004;109:849–854

34. Vehkavaara S, Yki-Järvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004;24:325–330

35. Taskinen MR, Kiusi T, Helve E, Nikkilä EA, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988;8:168–177

36. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653

37. Brohall G, Odén A, Fagerberg B. Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 2006;23:609–616

38. Miyashita Y, Nishimura R, Nemoto M, et al. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. Cardiovasc Diabetol 2008;7:16

39. Joya-Galeana J, Fernandez M, Cervera A, et al. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects. Diabetes Metab Res Rev 2011;27:373–382

40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589

41. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169